Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Find My GLP-1 PathSee my GLP-1 options & prices

By The RX Index Editorial Team · Last verified: April 1, 2026 · Sources: NEJM, The Lancet, Eli Lilly IR, FDA.gov, Reuters

Medication Guide · April 1, 2026

Orforglipron Reviews: Honest 2026 Verdict on Eli Lilly's GLP-1 Weight Loss Pill

Published: · Last updated:

Our verdict in one sentence:

In the pivotal Phase 3 obesity trial, the highest dose produced 11.2% average body weight loss over 72 weeks (12.4% among patients who stayed on treatment) — and it outperformed oral semaglutide head-to-head on both weight loss and blood sugar. The pill was FDA-approved on April 1, 2026 as Foundayo and is available now through LillyDirect and participating pharmacies. If you're switching from another GLP-1, Lilly's own ATTAIN-MAINTAIN trial showed that patients who switched from injectables to orforglipron maintained much of their weight loss.

Here's the reality of searching for “orforglipron reviews” right now: it was only FDA-approved on April 1, 2026, so real-world patient reviews are still emerging. What does exist is seven completed clinical trials, over 4,800 patients' worth of data, and a very clear picture of what this pill can and can't do.

We dug through all of it so you don't have to — the weight loss numbers separated by trial, side effects with real percentages, expected pricing Lilly has already committed to, head-to-head comparisons, and the question nobody else answers clearly: whether you should actually wait for it.

Orforglipron Reviews — once-daily oral GLP-1 pill by Eli Lilly. Small-molecule, non-peptide formula. No food or water timing restrictions in clinical trials.

What Is Orforglipron, Exactly?

Orforglipron is a once-daily oral GLP-1 weight loss pill made by Eli Lilly — the same company behind Mounjaro and Zepbound. Lilly describes it as the first oral small-molecule GLP-1 receptor agonist to successfully complete a Phase 3 trial, which means it's built differently from every other GLP-1 on the market.

Why the Small-Molecule Structure Matters

Current GLP-1 medications like Ozempic, Wegovy, and Zepbound are peptides — modified proteins that mimic a natural gut hormone called GLP-1. Proteins get destroyed by stomach acid, which is why most GLP-1 drugs need to be injected. The Wegovy pill uses special absorption enhancers and requires an empty stomach to protect the protein during digestion.

Orforglipron takes a completely different approach. It's a synthetic chemical compound — small enough to survive your digestive system intact and absorb directly through the gut wall. No special protections needed. In clinical trials, orforglipron was taken once daily without food or water timing restrictions.

This small-molecule structure also makes orforglipron cheaper and simpler to manufacture. Eli Lilly has said it can launch without supply constraints — a notable claim given the Ozempic and Mounjaro shortages that frustrated millions of patients.

What It Does in Your Body

Reduces appetite

You feel satisfied sooner and experience less 'food noise' between meals

Slows digestion

Food stays in your stomach longer, keeping you full

Improves insulin response

Particularly valuable for people with type 2 diabetes

Supports weight loss

Through the combined effect of eating less and improved metabolic function

Background: The drug was discovered by Chugai Pharmaceutical in Japan and licensed to Lilly in 2018. It has a half-life of 29–49 hours (supporting once-daily dosing). Seven Phase 2 and Phase 3 trials have been completed, enrolling over 4,800 patients across multiple countries.
How orforglipron works: GLP-1 receptor agonist that supports weight loss by reducing appetite and calorie intake, helps lower blood sugar, and is taken as a once-daily oral pill without food or water timing restrictions.

Should You Wait for Orforglipron or Start Something Now?

The short answer: Foundayo (orforglipron) is available now by prescription; you do not need to wait for its launch. But if you've been putting off treatment while waiting for the “perfect” option, you're losing time you won't get back. The best GLP-1 is the one you actually start.

We've seen this pattern with every new GLP-1 launch. People wait for Mounjaro. Then Zepbound. Then the Wegovy pill. Then orforglipron. Meanwhile, people who started six months ago are already seeing real results on the scale.

Consider discussing Foundayo with your prescriber if all three are true:

  1. 1.You specifically want a daily pill (not injections)
  2. 2.The Wegovy pill's fasting requirement (empty stomach + 30-min wait) is a dealbreaker
  3. 3.You can obtain a prescription and confirm availability and cost

Start an approved GLP-1 now if any of these are true:

  • →You've been 'about to start' for more than a month
  • →You want the strongest possible weight loss (injectables average 20%+ vs orforglipron's 11%)
  • →You'd rather start making progress this month than wait for a slightly more convenient option
  • →You're comfortable with weekly injections or the Wegovy pill's morning routine

The strongest argument against waiting:

Lilly's own ATTAIN-MAINTAIN trial showed that people who started on injectable Wegovy or Zepbound and then switched to orforglipron maintained much of their previously achieved weight loss — an average difference of just 0.9 kg after switching from Wegovy and 5.0 kg after switching from Zepbound over 52 weeks. You can start now and switch later. That's not a compromise — that's a strategy.

Discuss currently available GLP-1 options and any planned switch with your prescriber.

Foundayo is available now. Your prescriber can assess whether switching is appropriate.

Check Your Eligibility on Ro — FDA-Approved Programs → (sponsored affiliate link, opens in a new tab)

Or take our free 60-second matching quiz to find the right program for your situation.

Is Orforglipron Approved by the FDA?

Yes — FDA-approved April 1, 2026. Foundayo (orforglipron) received FDA approval for weight management in adults on April 1, 2026. It is available now through LillyDirect and licensed pharmacies with a valid prescription.

FDA approved Foundayo on April 1, 2026. Lilly announced availability through LillyDirect and telehealth providers, with retail distribution beginning April 9, 2026.

The current approval is for adult weight management; it is not an approval to treat type 2 diabetes.

Status DetailCurrent information
FDA approved?Yes — April 1, 2026
Available to the public?Yes — with a prescription
Lilly's public timelineU.S. launch began in April 2026
Reuters-reported target dateSuperseded by FDA approval on April 1, 2026
Submitted forObesity / overweight with comorbidities
Diabetes submissionSubmitted in 2026; FDA approval for diabetes has not been announced
Shipping readinessAvailable through LillyDirect and licensed pharmacies
Pre-manufactured supply~$1.5 billion worth
Also being studied forSleep apnea, hypertension, osteoarthritis

Sources: Eli Lilly official FAQ (Feb 2026), Reuters (Jan 2026), FDA.gov, BioSpace

Ready to discuss an approved GLP-1?

FDA-approved GLP-1 programs are available now through telehealth providers. Foundayo is available now; discuss any treatment change with your prescriber.

Check GLP-1 Eligibility on Ro — Available Now → (sponsored affiliate link, opens in a new tab)

How Much Weight Can You Actually Lose on Orforglipron?

Weight loss results vary by trial, dose, duration, and patient population. Here are all the numbers from every completed trial — separated so you can see exactly what was studied.

Orforglipron Weight Loss Results by Trial

TrialPatientsDurationBest Result (36 mg)PlaceboPublished
ATTAIN-1 (Ph 3)3,127 — obesity, no diabetes72 wks–11.2% / –12.4%*–2.1%NEJM, Sept 2025
ATTAIN-2 (Ph 3)Obesity + type 2 diabetes72 wks–10.5% / –22.9 lbs–2.2%Lancet, Nov 2025
Phase 2 (Obesity)272 — obesity/overweight36 wks–14.7% (45 mg)–2.3%NEJM, 2023
ACHIEVE-3 (Ph 3)1,698 — type 2 diabetes52 wks–9.2% / –19.7 lbsvs oral sema: –5.3%Lancet, Feb 2026
ACHIEVE-1 (Ph 3)559 — type 2 diabetes40 wks–7.9% / –16 lbs–1.6%NEJM, Jun 2025
ATTAIN-MAINTAINSwitched from Wegovy/Zepbound52 wksMaintained prior lossPlacebo regained ~9+ kgLilly PR, Dec 2025

*Treatment-regimen estimand includes all randomized patients regardless of whether they stayed on treatment. Efficacy estimand counts only those who completed treatment. Both are standard FDA reporting measures.

What these numbers mean in plain English:

If you weigh 220 pounds and take the highest dose for 72 weeks, you'd lose roughly 24–27 pounds on average. Some people in the trials lost significantly more — over half the patients on 36 mg lost at least 10%, and about a third lost 15% or more.

Those numbers are meaningful and comparable to what injectable GLP-1s achieved in their early trials. But they are lower than top-end results from injectable Zepbound (tirzepatide), which has shown 20%+ average weight loss in pivotal trials. That's an important distinction and we're not going to gloss over it.

The honest tradeoff:

Orforglipron does not deliver the highest weight loss numbers in the GLP-1 class. If raw maximum weight loss is your single top priority and you're fine with weekly injections, Zepbound is stronger. But orforglipron skips the needles, skips the fasting routine, and removes the barriers that keep millions of people from ever starting. A pill that people actually take consistently may produce better real-world outcomes than an injection they avoid.

What Are the Side Effects of Orforglipron?

The side effects are GI-heavy — diarrhea, nausea, constipation, and vomiting — which is consistent with other GLP-1 medications. In head-to-head testing, orforglipron caused more GI symptoms than oral semaglutide, but the vast majority were mild to moderate and improved over time. Let's look at the actual numbers instead of vague warnings.

Side Effect Rates From Phase 3 Trials (ACHIEVE-1)

Side EffectOrforglipron 36 mgOrforglipron 12 mgPlacebo
Diarrhea26%21%9%
Nausea16%18%2%
Dyspepsia15%20%7%
Constipation14%17%4%
Vomiting14%7%1%
Stopped due to side effects8%4%1%

Source: Eli Lilly ACHIEVE-1 Phase 3 results, published NEJM June 2025

What this actually means for you:

In ACHIEVE-3, about 58–59% of orforglipron patients reported GI symptoms versus 37–45% on oral semaglutide. The discontinuation rate was roughly 9.7% for orforglipron versus 4.9% for oral semaglutide. But flip the framing: roughly 90% of people on orforglipron stayed on treatment. Most dropouts happened during early dose escalation. If you push through that initial period (which your prescribing doctor manages with gradual dose increases), the side effects typically settle down.

No hepatic safety signal has been observed in Lilly's trial readouts to date. Overall safety has looked broadly consistent with the GLP-1 class.

Most common side effects reported in orforglipron clinical trials: diarrhea, nausea, constipation, vomiting, and dyspepsia. Gastrointestinal side effects were the most common and were mostly mild to moderate.

Tips That Actually Help With GLP-1 Side Effects

✓
Follow the dose titration schedule exactly. Your doctor will start you at a low dose and increase gradually. The escalation is designed specifically to minimize GI symptoms — don't try to jump ahead.
✓
Eat smaller, more frequent meals. Your stomach empties more slowly on GLP-1s. Large meals are more likely to trigger nausea. Aim for 4–5 smaller portions throughout the day.
✓
Prioritize protein. Protein keeps you satisfied, preserves muscle mass during weight loss, and tends to be better tolerated than fatty or carb-heavy foods during early treatment.
✓
Stay hydrated. Especially important if you experience diarrhea. Water, broth, and electrolyte drinks help.
✓
Cold water and ginger help nausea. Some users swear by ginger tea or ginger chews during the adjustment period.
✓
Be patient with yourself. Most side effects are worst in weeks 2–4 and improve significantly by weeks 6–8. The adjustment period is temporary — the results are what last.

Orforglipron vs. Current GLP-1 Options: The Full Picture

Here's how orforglipron stacks up against every approved GLP-1 option available right now — so you can make an honest comparison.

OptionFormatAvg. Weight LossKey AdvantageKey Limitation
OrforglipronDaily pill~11–12.4% (72 wks)No food rules, pill formatPrescription required; coverage varies
Wegovy pill (semaglutide 25mg)Daily pill~14–16.6%Available NOW, strong lossEmpty stomach + 30-min wait
Wegovy injectionWeekly injection~15%Proven CV benefit, 8+ years dataWeekly injection
Ozempic (diabetes)Weekly injection~12–14%Strong real-world track recordNot approved for weight loss
Zepbound (tirzepatide)Weekly injection~18–22%Highest weight loss in classWeekly injection
Compounded GLP-1Injection or tabletVariesLowest cost entry pointQuality and sourcing varies

Which Option Fits Your Situation?

You hate needles but want to start NOW →

The Wegovy pill

FDA-approved and available today. Yes, it has fasting requirements, but many people build the routine quickly — take it first thing with a small sip of water, wait 30 minutes, then eat breakfast.

You want the most weight loss possible →

Zepbound (tirzepatide)

The strongest option available. Injectable, weekly, but averaging over 20% weight loss in clinical trials — roughly 40–50 lbs for many patients. If results matter more than convenience, this is the clear choice.

You want orforglipron specifically →

Foundayo is available now.

Ask a licensed clinician whether Foundayo is appropriate, then confirm the dispensing channel, coverage, and cost.

You're already on a GLP-1 and want to switch to a pill later →

ATTAIN-MAINTAIN supports this pathway.

Foundayo is available now; talk to your current prescriber about whether a switch is appropriate. In the meantime, keep taking your current medication — stopping without a bridge leads to weight regain.

Orforglipron vs. The Wegovy Pill: Head-to-Head

Foundayo and the Wegovy pill are both available. ACHIEVE-3 compared orforglipron with oral semaglutide at diabetes doses, not with the Wegovy pill's 25 mg obesity dose; its results do not establish superiority over the Wegovy pill.

Here's what the ACHIEVE-3 trial showed, with a critical caveat most sites skip:

MeasureOrforglipron 36 mgOral Semaglutide 14 mg*
A1C reduction–2.2%–1.4%
Weight loss–19.7 lbs (9.2%)–11.0 lbs (5.3%)
GI side effects~58–59%~37–45%
Discontinuation (adverse events)~9.7%~4.9%
Food restrictionsNone in trialsEmpty stomach + 30-min wait

*Source: ACHIEVE-3, published in The Lancet, February 2026. *Critical caveat: semaglutide doses in this trial (7 mg and 14 mg) were Rybelsus diabetes doses, NOT the Wegovy pill's approved 25 mg obesity dose. We don't yet have a head-to-head trial vs. full-strength Wegovy pill. In separate trials, Wegovy pill at 25 mg showed ~14–16.6% weight loss vs. orforglipron's ~11.2–12.4%.

Daily routine comparison: Orforglipron routine in clinical trials — any time of day, no food timing rules, no water timing rules. Wegovy pill routine — must be taken in the morning on an empty stomach, with water only, then wait at least 30 minutes before eating.

Where orforglipron clearly wins: convenience.

No empty stomach. No 30-minute wait. No worrying about whether your morning routine will interfere with absorption. For parents with chaotic mornings, shift workers, travelers, or people with multiple daily medications, that fasting requirement is a daily annoyance that erodes adherence over time.

“The dosage requirements for oral Wegovy are not attractive to me, so orforglipron already has a leg up.”

— Public Reddit commenter, r/RoBody

How Much Will Orforglipron Cost?

LillyDirect self-pay pricing starts at $149/month. Higher doses cost up to $299/month with current offers, or $349/month for 14.5 mg and 17.2 mg without the refill offer. Continued eligibility for the $299 offer on those two doses requires refilling within 45 days. Eligible Medicare Part D beneficiaries can access Foundayo through the Medicare GLP-1 Bridge for a $50 monthly copay.

Expected Orforglipron Pricing vs. Current GLP-1 Costs

OptionSelf-Pay MonthlyMedicareNotes
Foundayo (orforglipron)$149–$299 with current offers; $349 for 14.5 mg or 17.2 mg without the refill offer$50/mo via BridgeVia LillyDirect; Medicare GLP-1 Bridge Jul 2026–Dec 2027 (BALANCE will not launch for Medicare Part D in 2027)
Wegovy pill$149–$299Varies by planAvailable now; via NovoCare/Ro
Wegovy injection~$199 intro, then ~$349CoveredIntro pricing for new self-pay patients
Zepbound$299–$699CoveredVia LillyDirect; lower doses more affordable
Compounded GLP-1 via MEDViStarting ~$179/moNot coveredCash-pay; includes clinical support

Last verified: April 1, 2026. Pricing may change. Sources: Eli Lilly (Nov 6, 2025 agreement), NovoCare, provider websites.

A note on Medicare: Eligible Medicare Part D beneficiaries can obtain Foundayo through the Medicare GLP-1 Bridge for a $50 monthly copay. The Bridge runs from July 1, 2026 through December 31, 2027 and does not require Part D plans to opt in. Clinical eligibility and prior authorization still apply. BALANCE will not launch in Medicare Part D in 2027.

What Do People Actually Say About Orforglipron?

Foundayo has been commercially available since April 2026, so retail patient reviews can exist. Individual reviews do not replace trial evidence, and the comments below are self-reported accounts, not verified clinical outcomes.

The comments below come from self-described users and earlier GLP-1 community discussions on Reddit. Statements about waiting for approval or launch reflect the time of those comments, not current availability.

“I do seem to feel full sooner and haven't really been craving food like I normally would.”

— Self-described orforglipron user, r/orforglipron

“It worked for me for 6 months (slow and steady weight loss) with minimal side effects.”

— Public Reddit commenter, r/orforglipron

“There's no fasting requirement with orforglipron so that seems easier to be on... but also who knows how soon it will actually be available once approved and maybe it's better to just get started on my weight loss journey.”

— Public Reddit commenter, r/WegovyPillWeightLoss

Our read on the forum chatter:

Foundayo's launch has already occurred. Current decisions should focus on clinical suitability, treatment goals, tolerability, coverage, and cost; a prescriber should guide any switch.

Can You Switch From Injections to Orforglipron Later?

Lilly's ATTAIN-MAINTAIN trial specifically tested this — and the topline results are encouraging. Patients who hit their weight loss plateau on injectable Wegovy or Zepbound switched to daily orforglipron for 52 weeks.

Wegovy → Orforglipron

+0.9 kg average regain over 52 weeks

Zepbound → Orforglipron

+5.0 kg average regain over 52 weeks

Placebo group

Regained ~9+ kg — confirming the drug effect

These are topline results from Lilly's press release (December 2025). Full peer-reviewed data will provide more detail on individual variation and long-term durability.

Think of it like training for a marathon.

You don't skip months of running waiting for better shoes. You start training now and upgrade when the shoes drop. The injectables are your training plan: powerful, proven, available now. Orforglipron is your long-term maintenance strategy: an oral option already available by prescription. One leads naturally into the other.

Start Your GLP-1 Program Now on Ro → (sponsored affiliate link, opens in a new tab)

The Bottom Line

Orforglipron is real. The data is strong. The FDA approved it on April 1, 2026 as Foundayo. It is the most convenient oral GLP-1 available — a once-daily pill with no food restrictions in trials, priced competitively, backed by seven clinical trials and thousands of patients' worth of evidence.

It is available now through LillyDirect, Ro, and retail pharmacies. Every week you spend waiting is a week you could have spent making progress.

The most common thing we hear from GLP-1 users across every platform is some version of: “I wish I had started sooner.” The regret is always about delay, never about action.

If you're ready to start now:

  • →Pick the GLP-1 option that fits your life today
  • →You can switch to orforglipron now that it's available
  • →ATTAIN-MAINTAIN data says switching works — starting now doesn't lock you in

If you're specifically holding out for orforglipron:

  • →Make it an active decision, not a passive one
  • →Have your plan ready — know which provider you'll use
  • →Know your budget; don't let 'waiting' become 'never starting'

Orforglipron: Frequently Asked Questions

Is orforglipron approved by the FDA?

Yes. Orforglipron (brand name Foundayo) was FDA-approved on April 1, 2026 for weight management in adults with obesity or overweight with at least one weight-related condition. It is available now through LillyDirect and participating pharmacies.

When will orforglipron be available?

Foundayo (orforglipron) was FDA-approved April 1, 2026 and became available through LillyDirect and pharmacies within days. Lilly had pre-manufactured approximately $1.5 billion worth of supply ahead of approval.

How much will orforglipron cost?

Self-pay pricing through LillyDirect starts at $149/month for the lowest dose and up to $299/month for higher doses with current offers, or $349/month for 14.5 mg and 17.2 mg without the refill offer. Medicare beneficiaries pay no more than $50/month through the Medicare GLP-1 Bridge (July 2026–December 2027), as Foundayo is included in the Bridge drug list. BALANCE is not launching for Medicare Part D in 2027.

What are the side effects of orforglipron?

The most common side effects are gastrointestinal: diarrhea, nausea, constipation, vomiting, and dyspepsia. These are consistent with the GLP-1 class and were mostly mild to moderate. In Phase 3 trials, treatment discontinuation due to adverse events ranged from about 4% to 10% depending on dose.

How much weight can you lose on orforglipron?

In the Phase 3 ATTAIN-1 trial (3,127 patients with obesity, 72 weeks), the highest dose (36 mg) produced 11.2% average body weight loss using the treatment-regimen estimand (12.4% using the efficacy estimand). In the earlier Phase 2 trial (272 patients, 36 weeks), weight loss reached up to 14.7%. Results vary by dose, duration, and population.

Is orforglipron better than the Wegovy pill?

In the ACHIEVE-3 head-to-head trial, orforglipron outperformed oral semaglutide on both blood sugar reduction and weight loss. However, that trial used lower semaglutide doses (7–14 mg) than the Wegovy pill's approved 25 mg obesity dose. Orforglipron also had higher GI side effects and discontinuation rates. Its major advantage is no food or water timing restrictions in trials.

Does orforglipron have to be taken on an empty stomach?

No. In clinical trials, orforglipron was taken once daily without food or water timing restrictions. This is a key advantage over the Wegovy pill, which requires an empty stomach and a 30-minute wait before eating or drinking.

Can you switch from injectable GLP-1s to orforglipron later?

Lilly's Phase 3 ATTAIN-MAINTAIN topline results showed that participants who switched from injectable Wegovy or Zepbound to orforglipron maintained much of their previously achieved weight loss over 52 weeks, with average regain of 0.9 kg (from Wegovy) and 5.0 kg (from Zepbound). This suggests starting injectables now and switching to the pill later is a viable strategy.

Will insurance cover orforglipron?

Foundayo is covered under the Medicare GLP-1 Bridge at $50/month for eligible Part D beneficiaries (July 2026–December 2027, 18 months). BALANCE will not launch for Medicare Part D in 2027 — CMS extended the Bridge instead. For commercial insurance, formulary decisions typically take months after approval — check with your plan.

Is orforglipron the same as tirzepatide or semaglutide?

No. Orforglipron is a different molecule entirely — a small-molecule, non-peptide GLP-1 receptor agonist. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are peptide-based incretin drugs. Semaglutide is available as both injections and tablets; tirzepatide is currently injectable only.

What is the brand name for orforglipron?

The brand name for orforglipron is Foundayo.

Should I wait for orforglipron or start a GLP-1 now?

Foundayo is available now, so there is no need to wait for its launch. Ask your prescriber whether it fits your needs. If you want to start losing weight now, FDA-approved GLP-1 programs are available today — and Lilly's ATTAIN-MAINTAIN trial showed that participants who switched from injectables to orforglipron maintained much of their weight loss over 52 weeks.

Sources

  1. Eli Lilly. “Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss” — ATTAIN-1 Phase 3 results. Published NEJM, September 2025.
  2. Eli Lilly. “What to Know About Orforglipron Oral GLP-1.” Last updated February 2026. lilly.com
  3. Eli Lilly. “Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins.” ATTAIN-MAINTAIN press release, December 18, 2025.
  4. Eli Lilly. ACHIEVE-1 press release / NEJM. June 2025.
  5. Reuters. “FDA delays decision for Lilly's obesity pill orforglipron.” January 2026.
  6. FDA. “FDA awards second batch of national priority vouchers.” November 2025.
  7. Jastreboff AM et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” NEJM, 2023.
  8. Rosenstock J et al. “Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3).” The Lancet, February 2026.
  9. Eli Lilly / U.S. Government agreement press release. November 6, 2025.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz. We'll ask about your goals, budget, insurance status, and preferences — and show you the 1–2 best options for your specific situation, whether that's considering Foundayo or another approved option.

Take the Free GLP-1 Matching Quiz →

Free · No signup · 60 seconds

This page is updated within 24 hours of any FDA action on orforglipron. Last verified: April 1, 2026.

The RX Index is an independent GLP-1 medication research platform. We are not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer. This page contains affiliate links to telehealth providers. Our editorial recommendations are based on independent research and are not influenced by affiliate compensation. See our full disclosure.

Your situation changes the answer

Find My GLP-1 Path

The right GLP-1 provider isn't the same for everyone. It depends on whether you'll use insurance or pay cash, whether you want an FDA-approved or compounded medication, your preferred route (injection or oral), and your budget. Answer a few questions in The RX Index's Find My GLP-1 Path tool to see a suggested provider route and pricing to review before you choose. It does not check your plan's coverage or copay; confirm those in your insurer's member portal or with the pharmacy-benefits number on your card.

  • What it asks: your goals, how you plan to pay, and your treatment preferences
  • What you get: a suggested provider route and pricing information to review
  • Cost: free · about 2 minutes · no signup
Find My GLP-1 Path